Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Phase 2

1(12.5%)

8Total

Phase 1(7)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02303678Phase 1Completed

D2C7 for Adult Patients With Recurrent Malignant Glioma

Role: lead

NCT06455605Phase 1Recruiting

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

Role: lead

NCT05734560Phase 1Recruiting

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Role: lead

NCT06177964Phase 2Recruiting

Lerapolturev (PVSRIPO) in GBM

Role: lead

NCT04160494Phase 1Active Not Recruiting

D2C7-IT With Atezolizumab for Recurrent Gliomas

Role: lead

NCT04547777Phase 1Recruiting

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Role: lead

NCT03973879Phase 1Withdrawn

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Role: lead

NCT04125719Phase 1Withdrawn

PVSRIPO in Combination With Nivolumab in Melanoma

Role: lead

All 8 trials loaded